{"count": 100, "results": [{"_id": "37417539", "pmid": 37417539, "pmcid": "PMC10327420", "title": "Impact of metformin on statin-associated myopathy risks in dyslipidemia patients", "journal": "Pharmacol Res Perspect", "authors": ["Bak K", "Moon S", "Ko M", "Choi YJ", "Shin S"], "date": "2023-08-01T00:00:00Z", "doi": "10.1002/prp2.1114", "meta_date_publication": "2023 Aug", "meta_volume": "11", "meta_issue": "4", "meta_pages": "e01114", "score": 50276.49, "text_hl": "Impact of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on statin-associated @DISEASE_Muscular_Diseases @DISEASE_MESH:D009135 @@@myopathy@@@ risks in @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@ patients", "citations": {"NLM": "Bak K, Moon S, Ko M, Choi YJ, Shin S. Impact of metformin on statin-associated myopathy risks in dyslipidemia patients Pharmacol Res Perspect. 2023 Aug;11(4):e01114. PMID: 37417539", "BibTeX": "@article{37417539, title={Impact of metformin on statin-associated myopathy risks in dyslipidemia patients}, author={Bak K and Moon S and Ko M and Choi YJ and Shin S}, journal={Pharmacol Res Perspect}, volume={11}, number={4}, pages={e01114}}"}}, {"_id": "33133865", "pmid": 33133865, "pmcid": "PMC7594657", "title": "Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence", "journal": "Cureus", "authors": ["Sahay RK", "Mittal V", "Gopal GR", "Kota S", "Goyal G", "Abhyankar M", "Revenkar S"], "date": "2020-09-28T00:00:00Z", "doi": "10.7759/cureus.10700", "meta_date_publication": "2020 Sep 28", "meta_volume": "12", "meta_issue": "9", "meta_pages": "e10700", "score": 50268.066, "text_hl": "The real-world analysis concludes that all the strengths of the @CHEMICAL_glimepiride @CHEMICAL_MESH:C057619 @@@glimepiride@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ combinations are widely prescribed in @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ with comorbidities like @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ and @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@ and complications for optimal glycemic control. ", "citations": {"NLM": "Sahay RK, Mittal V, Gopal GR, Kota S, Goyal G, Abhyankar M, Revenkar S. Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence Cureus. 2020 Sep 28;12(9):e10700. PMID: 33133865", "BibTeX": "@article{33133865, title={Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence}, author={Sahay RK and Mittal V and Gopal GR and Kota S and Goyal G and Abhyankar M and Revenkar S}, journal={Cureus}, volume={12}, number={9}, pages={e10700}}"}}, {"_id": "40834569", "pmid": 40834569, "title": "Pharmacological activation of Nrf2: Cardioprotective effects of statins and metformin against dyslipidemia-induced oxidative stress.", "journal": "Atherosclerosis", "authors": ["Mthembu SXH", "Mazibuko-Mbeje SE", "Ziqubu K", "Silvestri S", "Orlando P", "Nkambule BB", "Muller CJF", "Tiano L", "Dludla PV"], "date": "2025-08-07T00:00:00Z", "doi": "10.1016/j.atherosclerosis.2025.120474", "meta_date_publication": "2025 Aug 7", "meta_volume": "409", "meta_issue": "", "meta_pages": "120474", "score": 50264.457, "text_hl": "Pharmacological activation of @GENE_NFE2L2 @GENE_4780 @@@Nrf2@@@: Cardioprotective effects of statins and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ against @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@-induced oxidative stress.", "citations": {"NLM": "Mthembu SXH, Mazibuko-Mbeje SE, Ziqubu K, Silvestri S, Orlando P, Nkambule BB, Muller CJF, Tiano L, Dludla PV. Pharmacological activation of Nrf2: Cardioprotective effects of statins and metformin against dyslipidemia-induced oxidative stress. Atherosclerosis. 2025 Aug 7;409():120474. PMID: 40834569", "BibTeX": "@article{40834569, title={Pharmacological activation of Nrf2: Cardioprotective effects of statins and metformin against dyslipidemia-induced oxidative stress.}, author={Mthembu SXH and Mazibuko-Mbeje SE and Ziqubu K and Silvestri S and Orlando P and Nkambule BB and Muller CJF and Tiano L and Dludla PV}, journal={Atherosclerosis}, volume={409}, pages={120474}}"}}, {"_id": "32327628", "pmid": 32327628, "pmcid": "PMC7181777", "title": "Adjunctive metformin for antipsychotic-induced dyslipidemia: a meta-analysis of randomized, double-blind, placebo-controlled trials", "journal": "Transl Psychiatry", "authors": ["Jiang WL", "Cai DB", "Yin F", "Zhang L", "Zhao XW", "He J", "Ng CH", "Ungvari GS", "Sim K", "Hu ML", "Zheng W", "Xiang YT"], "date": "2020-04-23T00:00:00Z", "doi": "10.1038/s41398-020-0785-y", "meta_date_publication": "2020 Apr 23", "meta_volume": "10", "meta_issue": "1", "meta_pages": "117", "score": 50264.4, "text_hl": "Adjunctive @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ for antipsychotic-induced @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@: a meta-analysis of randomized, double-blind, placebo-controlled trials", "citations": {"NLM": "Jiang WL, Cai DB, Yin F, Zhang L, Zhao XW, He J, Ng CH, Ungvari GS, Sim K, Hu ML, Zheng W, Xiang YT. Adjunctive metformin for antipsychotic-induced dyslipidemia: a meta-analysis of randomized, double-blind, placebo-controlled trials Transl Psychiatry. 2020 Apr 23;10(1):117. PMID: 32327628", "BibTeX": "@article{32327628, title={Adjunctive metformin for antipsychotic-induced dyslipidemia: a meta-analysis of randomized, double-blind, placebo-controlled trials}, author={Jiang WL and Cai DB and Yin F and Zhang L and Zhao XW and He J and Ng CH and Ungvari GS and Sim K and Hu ML and Zheng W and Xiang YT}, journal={Transl Psychiatry}, volume={10}, number={1}, pages={117}}"}}, {"_id": "32982345", "pmid": 32982345, "pmcid": "PMC7495351", "title": "Lycopene Improves the Metformin Effects on Glycemic Control and Decreases Biomarkers of Glycoxidative Stress in Diabetic Rats", "journal": "Diabetes Metab Syndr Obes", "authors": ["Figueiredo ID", "Lima TFO", "Inácio MD", "Costa MC", "Assis RP", "Brunetti IL", "Baviera AM"], "date": "2020-09-07T00:00:00Z", "doi": "10.2147/DMSO.S265944", "meta_date_publication": "2020", "meta_volume": "13", "meta_issue": "", "meta_pages": "3117-3135", "score": 50262.465, "text_hl": "@CHEMICAL_Lycopene @CHEMICAL_MESH:D000077276 @@@Lycopene@@@ combined with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ may act synergistically in the control of postprandial @CHEMICAL_Blood_Glucose @CHEMICAL_MESH:D001786 @@@glycemia@@@, @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@ and glycoxidative stress, as well as increased antioxidant defenses, arising as a promising therapeutic strategy to mitigate @DISEASE_Diabetes_Complications @DISEASE_MESH:D048909 @@@diabetic complications@@@.", "citations": {"NLM": "Figueiredo ID, Lima TFO, Inácio MD, Costa MC, Assis RP, Brunetti IL, Baviera AM. Lycopene Improves the Metformin Effects on Glycemic Control and Decreases Biomarkers of Glycoxidative Stress in Diabetic Rats Diabetes Metab Syndr Obes. 2020;13():3117-3135. PMID: 32982345", "BibTeX": "@article{32982345, title={Lycopene Improves the Metformin Effects on Glycemic Control and Decreases Biomarkers of Glycoxidative Stress in Diabetic Rats}, author={Figueiredo ID and Lima TFO and Inácio MD and Costa MC and Assis RP and Brunetti IL and Baviera AM}, journal={Diabetes Metab Syndr Obes}, volume={13}, pages={3117-3135}}"}}, {"_id": "34335266", "pmid": 34335266, "pmcid": "PMC8319764", "title": "A Metabolic Pattern in Healthy Subjects Given a Single Dose of Metformin: A Metabolomics Approach", "journal": "Front Pharmacol", "authors": ["Dahabiyeh LA", "Mujammami M", "Arafat T", "Benabdelkamel H", "Alfadda AA", "Abdel Rahman AM"], "date": "2021-07-15T00:00:00Z", "doi": "10.3389/fphar.2021.705932", "meta_date_publication": "2021", "meta_volume": "12", "meta_issue": "", "meta_pages": "705932", "score": 50261.156, "text_hl": "The latter might contribute to the reported favorable effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@ in @DISEASE_Polycystic_Ovary_Syndrome @DISEASE_MESH:D011085 @@@PCOS@@@.", "citations": {"NLM": "Dahabiyeh LA, Mujammami M, Arafat T, Benabdelkamel H, Alfadda AA, Abdel Rahman AM. A Metabolic Pattern in Healthy Subjects Given a Single Dose of Metformin: A Metabolomics Approach Front Pharmacol. 2021;12():705932. PMID: 34335266", "BibTeX": "@article{34335266, title={A Metabolic Pattern in Healthy Subjects Given a Single Dose of Metformin: A Metabolomics Approach}, author={Dahabiyeh LA and Mujammami M and Arafat T and Benabdelkamel H and Alfadda AA and Abdel Rahman AM}, journal={Front Pharmacol}, volume={12}, pages={705932}}"}}, {"_id": "36176868", "pmid": 36176868, "pmcid": "PMC9511677", "title": "Role of Metformin in the Management of Polycystic Ovarian Syndrome-Associated Acne: A Systematic Review", "journal": "Cureus", "authors": ["Shamim H", "Jean M", "Umair M", "Muddaloor P", "Farinango M", "Ansary A", "Dakka A", "Nazir Z", "White CT", "Habbal AB", "Mohammed L"], "date": "2022-08-27T00:00:00Z", "doi": "10.7759/cureus.28462", "meta_date_publication": "2022 Aug", "meta_volume": "14", "meta_issue": "8", "meta_pages": "e28462", "score": 50257.18, "text_hl": "It also helps with metabolic comorbidities like @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ acts centrally via suppressing hypothalamic neurons potentially and growth differentiation factor @GENE_GDF15 @GENE_9518 @@@GDF-15@@@ by reducing @GENE_NPY @GENE_4852 @@@neuropeptide Y@@@ or by reducing appetite stimulation. ", "citations": {"NLM": "Shamim H, Jean M, Umair M, Muddaloor P, Farinango M, Ansary A, Dakka A, Nazir Z, White CT, Habbal AB, Mohammed L. Role of Metformin in the Management of Polycystic Ovarian Syndrome-Associated Acne: A Systematic Review Cureus. 2022 Aug;14(8):e28462. PMID: 36176868", "BibTeX": "@article{36176868, title={Role of Metformin in the Management of Polycystic Ovarian Syndrome-Associated Acne: A Systematic Review}, author={Shamim H and Jean M and Umair M and Muddaloor P and Farinango M and Ansary A and Dakka A and Nazir Z and White CT and Habbal AB and Mohammed L}, journal={Cureus}, volume={14}, number={8}, pages={e28462}}"}}, {"_id": "33439743", "pmid": 33439743, "title": "Metformin ameliorates ROS-p53-collagen axis of fibrosis and dyslipidemia in type 2 diabetes mellitus-induced left ventricular injury.", "journal": "Arch Physiol Biochem", "authors": ["Al-Ani B", "Alzamil NM", "Hewett PW", "Al-Hashem F", "Bin-Jaliah I", "Shatoor AS", "Kamar SS", "Latif NSA", "Haidara MA", "Dawood AF"], "date": "2021-01-13T00:00:00Z", "doi": "10.1080/13813455.2020.1869265", "meta_date_publication": "2021 Jan 13", "meta_volume": "", "meta_issue": "", "meta_pages": "1-7", "score": 50254.71, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ ameliorates ROS-@GENE_P53_PS @GENE_301300 @@@p53@@@-collagen axis of @DISEASE_Fibrosis @DISEASE_MESH:D005355 @@@fibrosis@@@ and @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@ in @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes mellitus@@@-induced @DISEASE_Ventricular_Dysfunction_Left @DISEASE_MESH:D018487 @@@left ventricular injury@@@.", "citations": {"NLM": "Al-Ani B, Alzamil NM, Hewett PW, Al-Hashem F, Bin-Jaliah I, Shatoor AS, Kamar SS, Latif NSA, Haidara MA, Dawood AF. Metformin ameliorates ROS-p53-collagen axis of fibrosis and dyslipidemia in type 2 diabetes mellitus-induced left ventricular injury. Arch Physiol Biochem. 2021 Jan 13;():1-7. PMID: 33439743", "BibTeX": "@article{33439743, title={Metformin ameliorates ROS-p53-collagen axis of fibrosis and dyslipidemia in type 2 diabetes mellitus-induced left ventricular injury.}, author={Al-Ani B and Alzamil NM and Hewett PW and Al-Hashem F and Bin-Jaliah I and Shatoor AS and Kamar SS and Latif NSA and Haidara MA and Dawood AF}, journal={Arch Physiol Biochem}, pages={1-7}}"}}, {"_id": "34825068", "pmid": 34825068, "pmcid": "PMC8605070", "title": "Metformin treatment reverses high fat diet- induced non-alcoholic fatty liver diseases and dyslipidemia by stimulating multiple antioxidant and anti-inflammatory pathways", "journal": "Biochem Biophys Rep", "authors": ["Yasmin T", "Rahman MM", "Khan F", "Kabir F", "Nahar K", "Lasker S", "Islam MD", "Hossain MM", "Hasan R", "Rana S", "Alam MA"], "date": "2021-11-17T00:00:00Z", "doi": "10.1016/j.bbrep.2021.101168", "meta_date_publication": "2021 Dec", "meta_volume": "28", "meta_issue": "", "meta_pages": "101168", "score": 50254.188, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ treatment reverses high @CHEMICAL_Fats @CHEMICAL_MESH:D005223 @@@fat@@@ diet- induced @DISEASE_Non_alcoholic_Fatty_Liver_Disease @DISEASE_MESH:D065626 @@@non-alcoholic fatty liver diseases@@@ and @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@ by stimulating multiple antioxidant and anti-@DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammatory@@@ pathways", "citations": {"NLM": "Yasmin T, Rahman MM, Khan F, Kabir F, Nahar K, Lasker S, Islam MD, Hossain MM, Hasan R, Rana S, Alam MA. Metformin treatment reverses high fat diet- induced non-alcoholic fatty liver diseases and dyslipidemia by stimulating multiple antioxidant and anti-inflammatory pathways Biochem Biophys Rep. 2021 Dec;28():101168. PMID: 34825068", "BibTeX": "@article{34825068, title={Metformin treatment reverses high fat diet- induced non-alcoholic fatty liver diseases and dyslipidemia by stimulating multiple antioxidant and anti-inflammatory pathways}, author={Yasmin T and Rahman MM and Khan F and Kabir F and Nahar K and Lasker S and Islam MD and Hossain MM and Hasan R and Rana S and Alam MA}, journal={Biochem Biophys Rep}, volume={28}, pages={101168}}"}}, {"_id": "35996967", "pmid": 35996967, "title": "Novel Emblica officinalis extract containing beta-glucogallin vs. metformin: a randomized, open-label, comparative efficacy study in newly diagnosed type 2 diabetes mellitus patients with dyslipidemia.", "journal": "Food Funct", "authors": ["Majeed M", "Mundkur L", "Paulose S", "Nagabhushanam K"], "date": "2022-09-22T00:00:00Z", "doi": "10.1039/d2fo01862d", "meta_date_publication": "2022 Sep 22", "meta_volume": "13", "meta_issue": "18", "meta_pages": "9523-9531", "score": 50252.656, "text_hl": "Novel Emblica officinalis extract containing @CHEMICAL_glucogallin @CHEMICAL_MESH:C060474 @@@beta-glucogallin@@@ vs. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@: a randomized, open-label, comparative efficacy study in newly diagnosed @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes mellitus@@@ @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@.", "citations": {"NLM": "Majeed M, Mundkur L, Paulose S, Nagabhushanam K. Novel Emblica officinalis extract containing beta-glucogallin vs. metformin: a randomized, open-label, comparative efficacy study in newly diagnosed type 2 diabetes mellitus patients with dyslipidemia. Food Funct. 2022 Sep 22;13(18):9523-9531. PMID: 35996967", "BibTeX": "@article{35996967, title={Novel Emblica officinalis extract containing beta-glucogallin vs. metformin: a randomized, open-label, comparative efficacy study in newly diagnosed type 2 diabetes mellitus patients with dyslipidemia.}, author={Majeed M and Mundkur L and Paulose S and Nagabhushanam K}, journal={Food Funct}, volume={13}, number={18}, pages={9523-9531}}"}}]}